BMC Team (formerly BTM Mazowsze) has been involved in numerous innovative biomedical and biotechnology projects.

We have set up 4 spin-offs:

  • IMNTA Sp. z o.o. (development of new antibacterial drugs)
  • GLIA Sp. z o.o. (development of new oncology drugs)
  • HUMON Sp. z o.o. (development of a technology platform for biomedicine)
  • Simplicardiac Sp. z o.o. (development of an innovative medical device)

We have obtained both private and public funding for three of the above mentioned companies (in total approx. 1.5 M EUR, including approx. 0.3 M EUR of private seed capital), and for one company we are negotiating public investment funding for approx. 0.25 M EUR. Additionally, 2 companies have already obtained second round funding from a venture capital investor.

We have initiated cooperation between science and industry in two projects:

  • Project MERIS – from mitochondria to innovative, protective cosmetics (Nencki Institute of Experimental Biology PAS – Dr Irena Eris S.A.)
  • Project INMET- an innovative programme supporting speech and cognitive disorders therapy (Nencki Institute of Experimental Biology PAS – Netiology Sp. z o.o.)

We have played a key role in obtaining approx. 1.1 M EUR in total for both projects, including several hundred thousand EUR of private seed capital.

We are directly involved in several projects led by research institutes and academia. These include:

  • ‘Innovative method of functional assessment of coronary artery stenosis, by means of in silico flow modelling, performed on the basis of multidetector computed tomography image’.

We have played a crucial role in obtaining approx. 0.9 M EUR funding for this project.

We have successfully assisted our customers in obtaining public funding for several projects. These include:

  • ‘From Basic to Translational Research in Oncology’, BASTION, funding of approx. 5.3 M EUR, Seventh Framework Programme.

Additionally, we have broad experience in smaller projects in the areas of technology transfer and transaction advisory services, including investment banking private placements.